JorgeE.(Cortes)Cortes-FrancoMD(He/Him)

PubMed

• EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review.
  Brenda Santellano, Rashi Agrawal, Gabriela Duchesne, Muhannad Sharara, E Andrew Balas, Gagan Agrawal, Meng-Han Tsai, Asha Nayak-Kapoor, Jorge E Cortes> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
• Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
  Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D Bledsoe, Naval G Daver, Elias J Jabbour, Tapan M Kadia, Zeev Estrov, Steven M Kornblau, Michael Andreeff, N...> ;Haematologica. 2024 Apr 4
• Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m) acute myeloid leukemia (AML).
  Brian A Jonas, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Jorge Cortes, Gary Schiller, Alice Mims, Gail J Roboz, Jus...> ;Leukemia & Lymphoma. 2024 Mar 27
• Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
  Rivera, D., Cui, W., Gao, J., Peker, D., Zhang, Q., Dewar, R., Qiu, L., Konoplev, S., Hu, Z., Sasaki, K., Hu, A., E, S., Liu, M., Fang, H., Wang, W., Tang, G., Apperle...> ;Modern Pathology. 2024 Feb 1
• 1 citations
  Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
  Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger, Elisabetta Abruzzese, Charles Chuah, Daniel J DeAngelo, Andreas Hochhaus, Jeffrey H Lipton...> ;Leukemia. 2024 Mar 1
• Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
  Lukas Veltmaat, Jorge Cortes> ;Blood. 2024 Mar 7
• Project Confirm: Accelerated Drug Approvals for CML-Response.
  Norsworthy, K. J., Norsworthy, K. J., Norsworthy, K. J., Kendra L Sweet, Jorge E Cortes, Jane F Apperley, Mel Mann, Michael J Mauro, Vivian G Oehler, Cristina Ruiz, Ch...> ;Clinical Cancer Research. 2024 Jan 5
• County-level colorectal cancer screening rates on colorectal cancer survival in the state of Georgia: Does county-level rurality matter?
  Tsai, M., Coughlin, S., Cortes, J.> ;Cancer Medicine. 2024 Jan 2
• Temporal trends in early-onset colorectal cancer incidence (2000-2020) by age group and five geographic regions in the state of Georgia.
  Tsai, M., Moore, J., Cabral, D., Rogers, C., Cortes, J.> ;American Journal of Cancer Research. 2024 Jan 1
• The interaction between social determinants of health and cervical cancer survival: A systematic review.
  Kellen Cristine Tjioe, Marisol Miranda-Galvis, Marian Symmes Johnson, Gagan Agrawal, E Andrew Balas, Jorge E Cortes> ;Gynecologic Oncology. 2024 Feb 1
• 1 citations
  Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia.
  Winn, A., Deininger, M., Moore, J., Shah, N., Flynn, K., Atallah, E., Cortes, J., Kota, V., Larson, R., Mauro, M., Oehler, V., Pinilla-Ibarz, J., Radich, J., Thompson, J.> ;JAMA Network Open. 2023 Dec 1
• A comparative safety review of targeted therapies for acute myeloid leukemia.
  Mark Dalgetty, Christian Leurinda, Cortes, J.> ;Expert Opinion on Drug Safety. 2023 Dec 18
• 2 citations
  Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.
  Fabio Efficace, Francesco Cottone, Betina Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci, Massimiliano Bonifacio, Andrea Patriarca, Isabella Capodanno, Maria C...> ;Cancer. 2024 Jan 1
• Ethno-demographic disparities in humoral responses to the COVID-19 vaccine among healthcare workers.
  Pankaj Ahluwalia, Ashutosh Vashisht, Harmanpreet Singh, Nikhil Shri Sahajpal, Ashis K Mondal, Kimya Jones, Jaspreet Farmaha, Ryan Bloomquist, Caroline Marie Carlock, D...> ;Journal of Medical Virology. 2023 Sep 1
• Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review.
  Marisol Miranda-Galvis, Kellen C Tjioe, E Andrew Balas, Gagan Agrawal, Jorge E Cortes> ;Blood Advances. 2023 Nov 14
• 3 citations
  Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
  Mikkael A Sekeres, Pau Montesinos, Jan Novak, Jianxiang Wang, Deepa Jeyakumar, Benjamin Tomlinson, Jiri Mayer, Erin Jou, Tadeusz Robak, David C Taussig, Hervé Dombret,...> ;Leukemia. 2023 Oct 1
• 1 citations
  Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia.
  May Garrett, Beverly Knight, Jorge E Cortes, Michael W Deininger> ;Cancer Medicine. 2023 Sep 1
• 1 citations
  Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results.
  Koji Sasaki, Kiyomi Morita, Hagop Kantarjian, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, William Wierda, Naval Daver, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Nov 1
• Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
  Jorge E Cortes, Jeff H Lipton, Vamsi Kota, Fausto Castagnetti, Sarit Assouline, Tim H Brümmendorf, Eric Leip, Andrea Viqueira, Carlo Gambacorti-Passerini> ;Haematologica. 2023 Dec 1
• Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.
  Jorge E Cortes, Delphine Rea, Michael J Mauro, Diana Tran, Pearl Wang, Kejal Jadhav, Aurore Yocolly, Koji Sasaki> ;Journal of Medical Economics. 2023 Jul 11
• 8 citations
  A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
  Nicholas J Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D Dinard...> ;Journal of Hematology & Oncology. 2023 Jul 8
• 2 citations
  Representation of the population in need for pivotal clinical trials in lymphomas.
  Mycal Casey, Lorriane Odhiambo, Nidhi Aggarwal, Mahran Shoukier, K M Islam, Jorge Cortes> ;Blood. 2023 Aug 31
• 3 citations
  Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers.
  Nikhil Shri Sahajpal, Ashis K Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R Hastie, Benjamin Hilton, Barbara R DuPont, Natasha M Sava...> ;Cancers. 2023 Jun 16
• 2 citations
  Teledermatology for skin cancer screening in rural Georgia utilizing teledermoscopy and distance learning: An ongoing report.
  Marisol Miranda-Galvis, Brenda Santellano Juarez, Kenza Mamouni, Lorriane Odhiambo, Samah Ibrahim, K M Monirul Islam, Rhea-Beth Markowitz, Koosh Desai, Harold Rabinovi...> ;JAAD International. 2023 Jun 1
• Quizartinib, the next FLT3 inhibitor.
  Jorge Cortes> ;Clinical Advances in Hematology & Oncology. 2023 May 1
• Join now to see all

Lectures

• Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial. 
  2019 ASCO Annual Meeting - 6/1/2019
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pregnancy Outcomes in Patients Treated with Bosutinib 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Cytogenetic Stratifications in Myelofibrosis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leu... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase 3, randomized, placebo-controlled trials evaluating glasdegib in combination with intensive or nonintensive chemotherapy in patients with untreated acute myeloid... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all